Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06738979
- Locations
- 🇨🇳
Hefei Third People's Hospital, Hefei, Anhui, China
🇨🇳Xuancheng People'S Hospital, Xuancheng, Anhui, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06711991
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Aerospace Center Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06706310
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT06702618
- Locations
- 🇨🇳
The First Affilliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳Harbin Medical University Cancer Hostipal, Harbin, Heilongjiang, China
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT06682169
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06672276
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital), Jinan, Shandong, China
🇨🇳The Second Hospital of Shandong University, Jinan, Shandong, China
Clinical Trial of TQB3002 in Patients With Advanced Cancers
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06662760
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
Drug-Drug Interaction (DDI) Study for TQB3616
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06662773
- Locations
- 🇨🇳
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06644417
- Locations
- 🇨🇳
Meng Chao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳Beijing Ditan Hospital Capital Medical University, Beijing, Beijing, China
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06598956
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital), Jinan, Shandong, China